(Q80130796)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

review article

1 reference

title

Linking oncogenic pathways with therapeutic opportunities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Andrea H Bild

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Anil Potti

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Joseph R Nevins

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

17 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

735-741

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc1976

28 December 2019

exact match

0 references

cites work

DNA microarrays in clinical oncology

1 reference

Genome-wide views of cancer

31 March 2020

1 reference

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

31 March 2020

1 reference

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

31 March 2020

1 reference

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

31 March 2020

1 reference

Molecular portraits of human breast tumours

31 March 2020

1 reference

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

31 March 2020

1 reference

Gene expression profiling predicts clinical outcome of breast cancer

31 March 2020

1 reference

A gene-expression signature as a predictor of survival in breast cancer

31 March 2020

1 reference

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

31 March 2020

1 reference

Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes

31 March 2020

1 reference

Gene expression predictors of breast cancer outcomes

31 March 2020

1 reference

Molecular diagnosis of Burkitt's lymphoma

31 March 2020

1 reference

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

31 March 2020

1 reference

Mining for regulatory programs in the cancer transcriptome

31 March 2020

1 reference

Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression

31 March 2020

1 reference

FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes

31 March 2020

1 reference

Gene expression phenotypic models that predict the activity of oncogenic pathways

31 March 2020

1 reference

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

31 March 2020

1 reference

An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.

31 March 2020

1 reference

Genetic regulators of large-scale transcriptional signatures in cancer

31 March 2020

1 reference

A genome-wide survey of RAS transformation targets

31 March 2020

1 reference

Gene expression profiling of fibroblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regulators.

31 March 2020

1 reference

A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis

31 March 2020

1 reference

A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer

31 March 2020

1 reference

Initiating oncogenic event determines gene-expression patterns of human breast cancer models

31 March 2020

1 reference

From signatures to models: understanding cancer using microarrays

31 March 2020

1 reference

Forensic genetics and ethical, legal and social implications beyond the clinic

31 March 2020

1 reference

Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data

31 March 2020

1 reference

A gene-coexpression network for global discovery of conserved genetic modules

31 March 2020

1 reference

Discovering molecular pathways from protein interaction and gene expression data

31 March 2020

1 reference

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

31 March 2020

1 reference

Significance analysis of functional categories in gene expression studies: a structured permutation approach

31 March 2020

1 reference

Discovering statistically significant pathways in expression profiling studies

31 March 2020

1 reference

Analysis of sample set enrichment scores: assaying the enrichment of sets of genes for individual samples in genome-wide expression profiles

31 March 2020

1 reference

Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors

31 March 2020

1 reference

Gene expression correlates of clinical prostate cancer behavior

31 March 2020

1 reference

Imatinib as a paradigm of targeted therapies

31 March 2020

1 reference

31 March 2020

Targeted cancer therapy

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

Trastuzumab in the treatment of breast cancer

31 March 2020

1 reference

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

31 March 2020

1 reference

Chemosensitivity prediction by transcriptional profiling

31 March 2020

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

31 March 2020

1 reference

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

31 March 2020

1 reference

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

31 March 2020

1 reference

Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer.

31 March 2020

1 reference

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

31 March 2020

1 reference

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

31 March 2020

1 reference

Tailoring Ras-pathway--inhibitor combinations for cancer therapy.

31 March 2020

1 reference

Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide

31 March 2020

1 reference

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours

31 March 2020

1 reference

mTOR, a new therapeutic target in acute myeloid leukemia

31 March 2020

1 reference

Targeting mTOR signaling for cancer therapy

31 March 2020

1 reference

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

31 March 2020

1 reference

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

31 March 2020

1 reference

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

31 March 2020

1 reference

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

31 March 2020

1 reference

Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy

31 March 2020

1 reference

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer

31 March 2020

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

31 March 2020

1 reference

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

31 March 2020

1 reference

Inhibitors of growth factor signalling

31 March 2020

1 reference

Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer

31 March 2020

1 reference

Sunitinib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

SU11248 and AG013736: current data and future trials in renal cell carcinoma

31 March 2020

1 reference

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

31 March 2020

1 reference

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

31 March 2020

1 reference

Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.

31 March 2020

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer

31 March 2020

1 reference

Where next for gefitinib in patients with lung cancer?

31 March 2020

1 reference

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

31 March 2020

1 reference

Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies

31 March 2020

1 reference

Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects.

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC1976

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915294%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

28 December 2019

0 references

1 reference